Clinical Epidemiological Profile and Global Survival in Patients with Pancreatic Adenocarcinoma at a Reference Hospital in Oncology

Authors

  • Wanessa Cristina Farias da Silva Hospital de Câncer de Pernambuco (HCP). Departamento de Ensino e Pesquisa (DEP). Santo Amaro. Recife (PE), Brasil. https://orcid.org/0000-0002-8022-0091
  • Ana Gabriela Silva de Lima Hospital de Câncer de Pernambuco (HCP). Departamento de Ensino e Pesquisa (DEP). Santo Amaro. Recife (PE), Brasil. https://orcid.org/0000-0001-9041-4618
  • Heverton Valentim Colaço da Silva Universidade Federal de Pernambuco (UFPE). Departamento de Patologia. Cidade Universitária. Recife (PE), Brasil. https://orcid.org/0000-0001-7169-4140
  • Rozangela Amorim Santos Hospital de Câncer de Pernambuco (HCP). Departamento de Ensino e Pesquisa (DEP). Santo Amaro. Recife (PE), Brasil. https://orcid.org/0000-0002-5289-999X

DOI:

https://doi.org/10.32635/2176-9745.RBC.2021v67n1.967

Keywords:

Pancreatic Neoplasms/epidemiology, Survival Analysis, Delayed Diagnosis

Abstract

Introduction: Pancreatic malignant neoplasia represents one of the highest mortality neoplasms worldwide, almost always associated to a dismal prognosis, especially when associated with lymphatic spread and to distant organs. Objective: To assess the global survival in patients with pancreatic adenocarcinoma treated at a specialized oncology center. Method: From January 2011 to December 2014, 71 medical records were retrospectively evaluated. The data were analyzed using the STATA software version 14, using the Kaplan-Meier curve and the Cox regression. The confidence interval used was 95% (p<0.05). Ethical and confidentiality principles have been secured. Results: There was predominance of males, mixed race and over 61 years of age at diagnosis. As for the clinical characteristics, 87.8% of the tumors were located in the head of the pancreas. Abdominal pain (92.7%) was the most frequent symptom, followed by progressive weight loss (79.3%) and jaundice (57.3%). The three-month follow-up survival rate was 48.4%. Conclusion: The study shows that pancreatic cancer has an extremely negative repercussion, since most patients are diagnosed in advanced stages of the disease, hindering the possibility of curative treatment.

Downloads

Download data is not yet available.

Published

2021-01-27

How to Cite

1.
Silva WCF da, Lima AGS de, Silva HVC da, Santos RA. Clinical Epidemiological Profile and Global Survival in Patients with Pancreatic Adenocarcinoma at a Reference Hospital in Oncology. Rev. Bras. Cancerol. [Internet]. 2021 Jan. 27 [cited 2024 Nov. 21];67(1):e-16967. Available from: https://rbc.inca.gov.br/index.php/revista/article/view/967

Issue

Section

ORIGINAL ARTICLE